Novartis AG（NVS）资讯与事件NVSNovartis AG

Major U.S. Averages Decline Amid Inflation Concerns

The major averages were broadly lower to start the month of September as inflation concerns and rising oil prices lifted bond yields in the U.S. and elsewhere. Worries continue to mount over whether the Federal Reserve will tighten monetary policy later this month.In other economic data news, the ISM Manufacturing PMI fell to 54.6 in August from July's near four-year high of 55.6, below market expectations of 55.2. The news comes as the JOLTS report said that job openings in the U.S. increased by 89,000 to 7.271M in July from a downwardly revised 7.182M in June. The openings figure came in below market expectations.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Medtronicreported, narrowed its FY27 earnings guide, and announced a $700M investment in Cornerstone RoboticsFervo Energyannounced awith GoogleJohn Ternus has officiallyof Apple, taking the reigns from Tim Cook, who will remain as executive chairAnthropic has entered into a $35B cloud compute deal with Nvidia-backedLambda,SpaceXis shaking up its data center team after facility issues,2. WALL STREET CALLS:Robinhoodto Overweight at Morgan Stanley on improved growth outlookMyriad Geneticsto Underweight from Overweight at Piper SandlerEvercoreDuolingoto Outperform on product improvementsBofAEdison Internationaland PG&Eto Neutral with California wildfire reform delayedRosenblattUberat Buy, Lyftat Neutral3. AROUND THE WEB:Novartishas paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after three patients died, Reuters reportsMagna Internationalis investing an additional $35M in Yuma Energy, a Bengaluru-based firm that operates a battery-swapping network for electric two- and three-wheelers, TechCrunch reportsChevronis finalizing a deal for the operating rights to two oilfields in Venezuela's Orinoco Belt that hold billions of barrels of heavy oil reserves, Bloomberg saysAirbnbhas started a pilot program with some hosts, lowering its take rate from bookings to either 6% or 10%, a significant reduction from the company average of 16%, Bloomberg reportsStellantisis halting production at its Mirafiori plant in Turin due to shortages of engine components following stronger-than-expected demand for hybrid vehicles, Reuters reports4. MOVERS:Comstock Resourcesgains after announcing awith the State Oil Company of the Azerbaijan Republic and a $450M joint venture with Jerry JonesCapricor Therapeuticsincreases after Piper Sandlerthe stock to OverweightKohl'shigher after naming Ryan Waymire asAlumislower after reporting itsdid not meet its primary and secondary endpointsEos Energyfalls after filing toof stock5. EARNINGS/GUIDANCE:Nioand provided guidance for Q3MiniMed, with EPS missing consensusYext, with EPS higher year-over-yearRegis, with CEO Susan Lintonsmith commenting on "a year of continued progress toward strengthening the foundation of our business"Broadcomon September 2INDEXES:Near midday, the Dow was down 211.32, or 0.40%, to 52,974.58, the Nasdaq was down 117.74, or 0.45%, to 26,253.15, and the S&P 500 was down 24.77, or 0.32%, to 7,661.37.

Stock Futures Weaker as Oil Prices Rise Above $90

Stock futures are pointing to a weaker open as investors begin September facing a renewed combination of geopolitical risk, higher oil prices and rising Treasury yields. Notably, ISM manufacturing data and the July JOLTS report are both due at 10 a.m. ET.Brent crude has climbed back above $90 a barrel, reviving concerns that an extended disruption to energy supplies could push inflation higher. At the same time, the 10-year Treasury yield climbed to roughly 4.75%, creating another headwind for equity valuations, particularly the high-growth technology and AI stocks that have driven much of this year's rally.In pre-market trading, S&P 500 futures fell 0.67%, Nasdaq futures fell 1.31% and Dow futures fell 0.64%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Fervo Energyup 14% after entering a 396-megawatt power purchase agreement with Googleto enable the continued development of the Cape Station enhanced geothermal systems GeoClusterNovartisup 6% after reporting topline results from its Phase 3 Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosisRobinhoodup 1% after Morgan Stanley upgraded the stock to Overweight with a price target of $150, up from $124UP AFTER EARNINGS -Regisup 3%Medtronicup 2%DOWN AFTER EARNINGS -MiniMeddown 7%LOWER -Microndown 2% afterMicron Taiwan announced that it will distribute record bonuses to its employees as the company's labor union plans a strikeCharterdown 1% after announcing that Jessica Fischer will step down from her current position as the company's CFO on October 15Niodown 1% after announcing it delivered 35,836 vehicles in August, nearly flat from July

Novartis Reports Positive Results for Remibrutinib in Relapsing Multiple Sclerosis Trials

Novartis announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib, a highly selective and potent oral Bruton's tyrosine kinase, BTK, inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate, ARR, and inflammatory brain lesions with a favorable safety profile. The results of the Remodel trials establish remibrutinib as a BTK inhibitor that achieved significant reductions in annualized relapse rate across two Phase III trials in adults with relapsing multiple sclerosis, RMS. Remibrutinib demonstrated clinically meaningful reductions versus teriflunomide in key secondary endpoints related to disability progression, with a positive trend in 3-month confirmed disability progression and nominal significance in 6-month confirmed disability progression in a preplanned combined analysis of Remodel-1/-2. Novartis will present the Remodel-1 and Remodel-2 data as a late-breaker at MSToronto2026 and intends to host an investor call following the congress presentation. Novartis plans to seek regulatory approval for remibrutinib in RMS globally.